פרופ' משה רכבי

Professor, Department of Physiology & Pharmacology, Sackler Faculty of Medicine

Dr. Miriam and Sheldon G. Adelson Chair in Biology of Addictive Diseases

Head, Varda and Shalom Yoram Institute for Human Genome Research

Education

Molecular Mechanisms of Drugs for Neuropsychiatric Disorders

Main projects in the lab include:

• Presynaptic monoamine transportes and the vesicular monoamine transporter as targets for neuropsychiatric drugs.
• Anxiolytic effects of new herbal treatment: mice models of anxiety and biochemical studies.
• Quaternary serotonin-reuptake inhibitors as novel anti-platelet drugs.
• Methylphenidate (Ritalin): abuse potential and long-term effects.
• Neuronal rescue by Rasagiline (MAO-B inhibitor) in thiamine deficiency.

Publications

Dror, V., Eliash, S., Rehavi, M., Assaf, Y., Biton I.E., Fattal-Valevsky, A. (2010). Neurodegeneration in thiamine deficient rats- A longitudal MRI study. Brain Res. 1308, 176-184.

Morag, A., Kirchheiner, J., Rehavi, M., and Gurwitz, D. (2010). Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics 11, 327-340.

Simchon, Y., Weizman, A., and Rehavi, M. (2010). The effect of methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD. Eur. Neuropsychopharmacol. 20, 714-720.

Valevsky, A., Pickholtz, E., Roz, N., Weizman, A., and Rehavi, M. (2010). Lack of modulatory effect of short-term repeated electroconvulsive therapy on platelet vesicular monoamine transporter 2 (VMAT2) in depressed patients. J. Neural. Transm.  117, 881-885.

Bismuth-Evenzal, Y., Roz, N., Gurwitz, D., and Rehavi, M. (2010). N-methyl-   Citalopram: A quaternary  selective serotonin uptake inhibitor. Biochem.  Pharmacol. 80, 1546-1552.

Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. (2011). Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 12:171-84.

Zalsman G, Rehavi M, Roz N, Laor N, Weizman A, Toren P. (2011). Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression. J Neural Transm. 118:1383-7.

Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. (2012). Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord. 136:99-103

Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M, Stingl JC, Gurwitz D. (2012) Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 13:1129-39.

Doron R, Lotan D, Rak-Rabl A, Raskin-Ramot A, Lavi K, Rehavi M. (2012) Anxiolytic effects of a novel herbal treatment in mice models of anxiety. Life Sci. 90:995-1000

Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N*, Gurwitz D*. (2013) Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry. 3:e313.

Doron R, Lotan D, Einat N, Yaffe R, Winer A, Marom I, Meron G, Kately N, Rehavi M (2014) A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice. Life Sci. 94:151-7

Dror V, Rehavi M, Biton IE, Eliash S. (2014) Rasagiline prevents neurodegeneration in thiamine deficient rats-A longitudinal MRI study. Brain Res. 1557:43-54

Kornilov P, Peretz A, Lee Y, Son K, Lee JH, Refaeli B, Roz N, Rehavi M, Choi S, Attali B. (2014) Promiscuous gating modifiers target the voltage sensor of Kv7.2, TRPV1, and Hv1 cation channels. FASEB J. 28:2591-602

Doron R, Lotan D, Versano Z, Benatav L, Franko M, Armoza S, Kately N, Rehavi M (2014) Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications. PLoS One 9:e91455

Grants

2011-2015       Novel herbal treatment for anxiety disorder, Israel Science Foundation